PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
We would like to announce that MultiplexDX was successfully awarded a grant from the Slovak Ministry of Health. The grant, entitled MIRNETDX, will focus on identifying novel microRNA biomarker signatures for diagnosing pancreatic neuroendocrine tumors. This project builds on a long-lived collaboration between Dr. Pavol Čekan, CEO of MultiplexDX, and Dr. Neil Renwick, Assistant Professor from Queen’s University in Canada, since they were postdoctoral fellows at Rockefeller University (2009-2013), where they co-developed novel microRNA-based cancer diagnostic technologies.
Dr. Peter Kilian, COO of MultiplexDX said:
“MicroRNA-375 is a promissing biomarker for neuroendocrine tumors, more specificaly in the case of pancreatic cancer. Since there’s no specific and reliable diagnostic method for neuroendocrine tumors, we’re excited to explore the possibility to plug this hole in the diagnostic market!“
The project focuses on development and pre-clinical validation of novel, precise and early diagnostics of pancreatic neuroendocrine tumors (pNETs) using miRNA signatures. MIRNETDX proposes to develop novel, multiplexed and quantitative miRNA FISH with highly specific miRNA probes, enhancing signal-to-noise ratio as well as improving miRNA sequencing by eliminating technical and methodological biases. By combining these great advances in microRNA sequencing and microRNA FISH to quantify and visualize microRNA expression patterns in pNETs, we aim to discover novel microRNA “signatures” that are specific to pNETs and, therefore, can be used for diagnostic and therapeutic purposes. We also aim to detect and quantify circulating pNET-specific miRNAs in blood plasma for an early diagnosis of pNET patients.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.